© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 3, 236-244,
February 3, 1999
© 1999 Oxford University Press
ARTICLES |
The ras Oncogene-Mediated Sensitization of Human Cells to Topoisomerase II Inhibitor-Induced Apoptosis
Affiliations of authors: H.-M. Koo, M. J. McWilliams, M.Jeffers (ABL—Basic Research Program), M. Gray-Goodrich, A. Vaigro-Wolff, A. Monks (Science Applications International Corporation—Frederick), W. G. Alvord (Data Management Services, Inc.), National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD; G. Kohlhagen, Y. Pommier (Laboratory of Molecular Pharmacology, Division of Cancer Treatment), K. D. Paull (deceased) (Information Technology Branch, Developmental Therapeutics Program, Division of Cancer Treatment), G. F. Vande Woude (Division of Basic Sciences), National Cancer Institute, Bethesda, MD.
Correspondence to: George F. Vande Woude, Division of Basic Sciences, NCI-Frederick Cancer Research and Development Center, P.O. Box B, Bldg. 469, Frederick, MD 21702 (e-mail: woude{at}ncifcrf.gov).
BACKGROUND: Among the inhibitors of the enzyme topoisomerase II (an important target for chemotherapeutic drugs) tested in the National Cancer Institute's In Vitro Antineoplastic Drug Screen, NSC 284682 (3'-hydroxydaunorubicin) and NSC 659687 [9-hydroxy-5,6-dimethyl-1-(N-{2(dimethylamino)ethyl}carbamoyl)-6H-pyrido-(4,3-b)carbazole] were the only compounds that were more cytotoxic to tumor cells harboring an activated ras oncogene than to tumor cells bearing wild-type ras alleles. Expression of the multidrug resistance proteins P-glycoprotein and MRP (multidrug resistance-associated protein) facilitates tumor cell resistance to topoisomerase II inhibitors. We investigated whether tumor cells with activated ras oncogenes showed enhanced sensitivity to other topoisomerase II inhibitors in the absence of the multidrug-resistant phenotype. METHODS: We studied 20 topoisomerase II inhibitors and individual cell lines with or without activated ras oncogenes and with varying degrees of multidrug resistance. RESULTS: In the absence of multidrug resistance, human tumor cell lines with activated ras oncogenes were uniformly more sensitive to most topoisomerase II inhibitors than were cell lines containing wild-type ras alleles. The compounds NSC 284682 and NSC 659687 were especially effective irrespective of the multidrug resistant phenotype. The ras oncogene-mediated sensitization to topoisomerase II inhibitors was far more prominent with the non-DNA-intercalating epipodophyllotoxins than with the DNA-intercalating inhibitors. This difference in sensitization appears to be related to a difference in apoptotic sensitivity, since the level of DNA damage generated by etoposide (an epipodophyllotoxin derivative) in immortalized human kidney epithelial cells expressing an activated ras oncogene was similar to that in the parental cells, but apoptosis was enhanced only in the former cells. CONCLUSIONS: Activated ras oncogenes appear to enhance the sensitivity of human tumor cells to topoisomerase II inhibitors by potentiating an apoptotic response. Epipodophyllotoxin-derived topoisomerase II inhibitors should be more effective than the DNA-intercalating inhibitors against tumor cells with activated ras oncogenes.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther., June 1, 2006; 5(6): 1387 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. V. Woude, G. J. Kelloff, R. W. Ruddon, H.-M. Koo, C. C. Sigman, J. C. Barrett, R. W. Day, A. P. Dicker, R. S. Kerbel, D. R. Parkinson, et al. Reanalysis of Cancer Drugs: Old Drugs, New Tricks Clin. Cancer Res., June 1, 2004; 10(11): 3897 - 3907. [Full Text] [PDF]
|
|
|
|
|
|
L. Maggiorella, V. Frascogna, M.-G. Poullain, M. Berlion, C. Lucas, S. Douc Razy, F. Eschwege, and J. Bourhis The Olivacine S16020 Enhances the Antitumor Effect of Ionizing Radiation without Increasing Radio-induced Mucositis Clin. Cancer Res., July 1, 2001; 7(7): 2091 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q.-B. She, A. M. Bode, W.-Y. Ma, N.-Y. Chen, and Z. Dong Resveratrol-induced Activation of p53 and Apoptosis Is Mediated by Extracellular- Signal-regulated Protein Kinases and p38 Kinase Cancer Res., February 1, 2001; 61(4): 1604 - 1610. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. W. Stacey, M. Hitomi, and G. Chen Influence of Cell Cycle and Oncogene Activity upon Topoisomerase IIalpha Expression and Drug Toxicity Mol. Cell. Biol., December 15, 2000; 20(24): 9127 - 9137. [Abstract] [Full Text]
|
|
|
|
|
|
H. Malonne, S. Farinelle, C. Decaestecker, L. Gordower, J. Fontaine, F. Chaminade, J.-M. Saucier, G. Atassi, and R. Kiss In Vitro and in Vivo Pharmacological Characterizations of the Antitumor Properties of Two New Olivacine Derivatives, S16020-2 and S30972-1 Clin. Cancer Res., September 1, 2000; 6(9): 3774 - 3782. [Abstract] [Full Text]
|
|
|
|
|
|
H.-M. Koo, M. J. McWilliams, W. G. Alvord, and G. F. Vande Woude Ras Oncogene-Induced Sensitization to 1-{{beta}}-D-Arabinofuranosylcytosine Cancer Res., December 1, 1999; 59(24): 6057 - 6062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-M. Koo and G. F. Vande Woude Re: The ras Oncogene-Mediated Sensitization of Human Cells to Topoisomerase II Inhibitor-Induced Apoptosis J Natl Cancer Inst, November 17, 1999; 91(22): 1969 - 1969. [Full Text] [PDF]
|
|
|
|
 |
|
 H.-M. Koo, M. VanBrocklin, M. J. McWilliams, S. H. Leppla, N. S. Duesbery, and G. F. V. Woude Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase PNAS, March 5, 2002; 99(5): 3052 - 3057. [Abstract] [Full Text] [PDF]
|
|